Clear Search

Showing 1 result for “refractory subacute cutaneous lupus erythematosus” published 2022.

January 2022

Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib

Clin Exp Dermatol. 2021. Epub ahead of print

Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.

more…